These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16775614)

  • 1. Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm.
    Mundle SD; Raza A
    Leukemia; 2006 Sep; 20(9):1481-3. PubMed ID: 16775614
    [No Abstract]   [Full Text] [Related]  

  • 2. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
    Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes.
    Laporte JP; Isnard F; Fenaux P; Woler M; Najman A
    Contrib Nephrol; 1991; 88():271-2; discussion 273-5. PubMed ID: 2040189
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes.
    Haematologica; 1999 Dec; 84(12):1057. PubMed ID: 10586204
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin in myelodysplastic syndromes: durable response in a young patient.
    Aloe Spiriti MA; Latagliata R; Petti MC
    Haematologica; 1996; 81(4):381-2. PubMed ID: 8870388
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical application of recombinant erythropoietin in myelodysplasia.
    Mittelman M; Lessin LS
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):993-1009. PubMed ID: 7852220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
    Kurzrock R; Talpaz M; Estey E; O'Brien S; Estrov Z; Gutterman JU
    Leukemia; 1991 Nov; 5(11):985-90. PubMed ID: 1961041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of erythropoietin (EPO) in oncology.
    Oster W; Schindel F; Heinrichs H
    Behring Inst Mitt; 1991 Dec; (90):62-8. PubMed ID: 1801692
    [No Abstract]   [Full Text] [Related]  

  • 9. A strategy for erythropoietin treatment in myelodysplastic syndromes.
    Hast R
    Med Oncol; 1999 Sep; 16(3):188-90. PubMed ID: 10523798
    [No Abstract]   [Full Text] [Related]  

  • 10. [The benefits of treatment with recombinant human erythropoietin in cancer patients].
    Solignac M;
    Presse Med; 2003 Sep; 32(29):1373-7. PubMed ID: 14534503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant erythropoietin in myelodysplastic syndromes: whom to treat and how? More questions than answers.
    Mittelman M
    Acta Haematol; 1993; 90(2):53-7. PubMed ID: 8285018
    [No Abstract]   [Full Text] [Related]  

  • 12. Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes.
    Musto P
    Clin Lymphoma; 2005 Jun; 6(1):52-5. PubMed ID: 15989709
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes.
    Ribatti D
    Leukemia; 2002 Sep; 16(9):1890; author reply 1891. PubMed ID: 12200722
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes.
    Razzano M; Caslini C; Cortelazzo S; Battistel V; Rambaldi A; Barbui T
    Br J Haematol; 1992 Aug; 81(4):628-30. PubMed ID: 1390262
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin and the myelodysplastic syndrome.
    Jacobs A; Culligan D; Bowen D
    Contrib Nephrol; 1991; 88():266-70. PubMed ID: 2040188
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
    Azzarà A; Carulli G; Galimberti S; Baratè C; Fazzi R; Cervetti G; Petrini M
    Am J Hematol; 2011 Sep; 86(9):762-7. PubMed ID: 21850658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.
    Remacha AF; Arrizabalaga B; Bueno J; Muñoz J; Bargay J; Pedro C
    Haematologica; 2010 Feb; 95(2):339-40. PubMed ID: 20139394
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A; Shibata A
    Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.